National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 11/26/2021 release of VAERS data:

Found 4,760 cases where Vaccine is HPV2

Government Disclaimer on use of this data



Case Details

This is page 5 out of 476

Result pages: prev   1 2 3 4 5 6 7 8 9 10 11 12 13 14   next


VAERS ID: 428947 (history)  
Form: Version 1.0  
Age: 18.0  
Sex: Female  
Location: New Jersey  
Vaccinated:2011-07-14
Onset:2011-07-24
   Days after vaccination:10
Submitted: 2011-08-06
   Days after onset:13
Entered: 2011-08-06
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 1 RA / -
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / 2 RA / -
TDAP: TDAP (NO BRAND NAME) / UNKNOWN MANUFACTURER - / 1 RA / -

Administered by: Unknown       Purchased by: Private
Symptoms: Blood test normal, Headache, Pyrexia
SMQs:, Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations: headache/fever~Meningococcal (no brand name)~UN~0.00~Patient|headache/fever~Tdap (no brand name)~UN~0.00~Patient|headache,fever~
Other Medications:
Current Illness: NO
Preexisting Conditions: No
Allergies:
Diagnostic Lab Data: Doctor did blood work and results were negative.
CDC Split Type:

Write-up: Started with headaches 9 days after Cervarix vaccine. Began to run fever in the evening on 8/3/2011 for 3 days. Doctor did a full blood work and everything came back negative.


VAERS ID: 432680 (history)  
Form: Version 1.0  
Age: 11.0  
Sex: Female  
Location: New Jersey  
Vaccinated:2010-11-20
Onset:2010-11-20
   Days after vaccination:0
Submitted: 2011-08-04
   Days after onset:256
Entered: 2011-08-09
   Days after submission:5
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
FLU3: INFLUENZA (SEASONAL) (AFLURIA) / CSL LIMITED - / UNK UN / UN
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK UN / UN
HPV4: HPV (GARDASIL) / MERCK & CO. INC. 0768Z / 1 UN / UN
TDAP: TDAP (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Pyrexia
SMQs:, Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? Yes
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: None
Allergies:
Diagnostic Lab Data: None
CDC Split Type: WAES1011USA02964

Write-up: Information has been received from an office manager concerning an 11 year old female with no pertinent medical history and no drug reaction who on 20-NOV-2010 was vaccinated with the first dose of GARDASIL (lot# 666597/0768Z) (route, dose not reported) and CERVARIX. Second suspect therapy included AFLURIA (manufacturer unknown). Other concomitant therapy included diphtheria toxoid (+) pertussis acellular vaccine (unspecified) (+) tetanus toxoid. It was reported that the patient was being seen in the office due to a 104F fever on 22-NOV-2010. No lab diagnostics study was performed. At the time of reporting, the patient was not recovered. Additional information has been requested.


VAERS ID: 430308 (history)  
Form: Version 1.0  
Age: 14.0  
Sex: Unknown  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2011-08-18
Entered: 2011-08-18
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Autoimmune disorder, Muscle atrophy, Polyneuropathy
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Delayed motor skills
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0740267A

Write-up: This case was reported in a literature article and described the occurrence of muscle atrophy in a 14-year-old subject of unspecified gender who was vaccinated with HPV vaccine (manufacturer unspecified). Concurrent medical conditions included delayed early gross motor. On an unspecified date, the subject received unspecified dose of HPV vaccine (administration site and route unknown, batch number not provided). 90 days after vaccination with HPV vaccine, the subject experienced primary muscular atrophy and autoimmune polyneuropathy. This case was assessed as medically serious by GSK. At the time of reporting, the outcome of the events was unspecified. The author considered the events were unlikely to be related to vaccination with HPV vaccine. This case has been linked to case B0739797A: same literature article. Summary of the literature article: In 2004 the Clinical Consult Case Review (CCCR) working group was formed within the CDC-funded Clinical Immunization Safety Assessment (CISA) Network to review additional cases of adverse events following immunizations (AEFI). Cases were referred by practitioners, health departments, or CDC employees. Vaccine Adverse Event Reporting System (VAERS) searches and literature reviews for similar cases were performed prior to review. After CCCR discussion. AEFI were assessed for a causal relationship with vaccination and recommendations regarding future immunizations were relayed back to the referring physicians. In 2010, surveys were sent to referring physicians to determine the utility and effectiveness of the CCCR service. CISA investigators reviewed 76 cases during 68 conference calls between April 2004 and December 2009. Almost half of the cases (35/76) were neurological in nature. Similar AEFI for the specific vaccines received were discovered for 63 cases through VAERS searches and for 38 cases through PubMed searches. Causality assessment using the modified WHO criteria resulted in classifying 3 cases as definitely related to vaccine administration, 12 as probably related, 16 as possibly related, 18 as unlikely related, 10 as unrelated, and 17 had insufficient information to assign causality. The physician satisfaction survey was returned by 30 (57.7%) of those surveyed and a majority of respondents (93.3%) felt that the CCCR service was useful. The author''s conclusion stated that the CCCR provides advice about AEFI to practitioners, assigns potential causality, and contributes to an improved understanding of adverse health events following immunizations.


VAERS ID: 430354 (history)  
Form: Version 1.0  
Age: 26.0  
Sex: Unknown  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2011-08-18
Entered: 2011-08-18
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK UN / UN

Administered by: Other       Purchased by: Other
Symptoms: VIIth nerve paralysis
SMQs:, Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious meningitis (broad), Hearing impairment (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0740283A

Write-up: This case was reported in a literature article and described the occurrence of Bell''s palsy in a 26-year-old subject of unspecified gender who was vaccinated with HPV vaccine (manufacturer unspecified). No past medical history, the subject was healthy. On an unspecified date, the subject received an unspecified dose of HPV vaccine (administration site and route unknown, batch number not provided). At an unspecified time after vaccination with HPV vaccine, the subject experienced Bell''s palsy. This case was assessed as medically serious by GSK. At the time of reporting, the outcome of the event was unspecified. This case has been linked to case B0739797A: same literature article. Summary of the literature article: In 2004 the Clinical Consult Case Review (CCCR) working group was formed within the CDC-funded Clinical Immunization Safety Assessment (CISA) Network to review individual cases of adverse events following immunizations (AEFI). Cases were referred by practitioners, health departments, or CDC employees. Vaccine Adverse Event Reporting System (VAERS) searches and literature reviews for similar cases were performed prior to review. After CCCR discussion, AEFI were assessed for a causal relationship with vaccination and recommendations regarding future immunizations were relayed back to the referring physicians. In 2010, surveys were sent to referring physicians to determine the utility and effectiveness of the CCCR service. CISA investigators reviewed 76 cases during 68 conference calls between April 2004 and December 2009. Almost half of the cases (35/76) were neurological in nature. Similar AEFI for the specific vaccines received were discovered for 63 cases through VAERS searches and for 38 cases through PubMed searches. Causality assessment using the modified WHO criteria resulted in classifying 3 cases as definitely related to vaccine administration, 12 as probably related, 16 as possibly related, 18 as unlikely related, 10 as unrelated, and 17 had insufficient information to assign causality. The physician satisfaction survey was returned by 30 (57.7%) of those surveyed and a majority of respondents (93.3%) felt that the CCCR service was useful. The author''s conclusion stated that the CCCR provides advice about AEFO to practitioners, assigns potential causality, and contributes to an improved understanding of adverse health events following immunizations.


VAERS ID: 430365 (history)  
Form: Version 1.0  
Age: 21.0  
Sex: Unknown  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2011-08-18
Entered: 2011-08-18
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / UNK UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Amyotrophic lateral sclerosis, Cervicobrachial syndrome, Guillain-Barre syndrome, Pharyngeal disorder
SMQs:, Peripheral neuropathy (narrow), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Hypothyroidism; Motor developmental delay
Preexisting Conditions: Purpura fulminans; Varicella
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: B0740269A

Write-up: This case was reported in a literature article and described the occurrence of amyotrophic lateral sclerosis in a 21-year-old subject of unspecified gender who was vaccinated with HPV vaccine (manufacturer unspecified). The subject''s medical history included purpura fulminans and varicella. Concurrent medical conditions included hypothyroidism and motor developmental delay. On an unspecified date, the subject received an unspecified dose of HPV vaccine (administration site and route unknown, batch number not provided). 270 days after vaccination with HPV vaccine, the subject experienced amyotrophic lateral sclerosis and pharyngeal-cervical brachial variant Guillain Barre syndrome. This case was assessed as medically serious by GSK. At the time of reporting, the outcome of the events was unspecified. The author considered the events were unlikely to be related to vaccination with HPV vaccine. This case has been linked to case B0739797A : same literature article. Summary of the literature article: In 2004 the Clinical Consult Case Review (CCCR) working group was formed within the CDC-funded Clinical Immunization Safety Assessment (CISA) Network to review individual cases of adverse events following immunizations (AEFI). Cases were referred by practitioners, health departments, or CDC employees. Vaccine Adverse Event Reporting System (VAERS) searches and literature reviews for similar cases were performed prior to review. After CCCR discussion, AEFI were assessed for a causal relationship with vaccination and recommendations regarding future immunizations were relayed back to the referring physicians. In 2010, surveys were sent to referring physicians to determine the utility and effectiveness of the CCCR service. CISA investigators reviewed 76 cases during 68 conference calls between April 2004 and December 2009. Almost half of the cases (35/76) were neurological in nature. Similar AEFI for the specific vaccines received were discovered for 63 cases through VAERS searches and for 38 cases through PubMed searches. Causality assessment using the modified WHO criteria resulted in classifying 3 cases as definitely related to vaccine administration, 12 as probably related, 16 as possibly related, 18 as unlikely related, 10 as unrelated, and 17 had insufficient information to assign causality. The physician satisfaction survey was returned by 30 (57.7%) of those surveyed and a majority of respondents (93.3%) felt that the CCCR service was useful. The author''s conclusion stated that the CCCR provides advice about AEFO to practitioners, assigns potential causality, and contributes to an improved understanding of adverse health events following immunizations.


VAERS ID: 433261 (history)  
Form: Version 1.0  
Age: 13.0  
Sex: Female  
Location: California  
Vaccinated:2011-04-12
Onset:2011-04-12
   Days after vaccination:0
Submitted: 2011-07-18
   Days after onset:97
Entered: 2011-08-23
   Days after submission:36
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (HAVRIX) / GLAXOSMITHKLINE BIOLOGICALS AHAVB498AA / 1 UN / UN
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA113AA / 1 LA / UN
MMR: MEASLES + MUMPS + RUBELLA (MMR II) / MERCK & CO. INC. 1059Z / 2 UN / UN
MNQ: MENINGOCOCCAL CONJUGATE (MENACTRA) / SANOFI PASTEUR U3765AA / 1 UN / UN
TDAP: TDAP (ADACEL) / SANOFI PASTEUR U3874AA / UNK UN / UN
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. 1377Z / 1 UN / UN

Administered by: Private       Purchased by: Private
Symptoms: Asthenia, Dizziness, Headache, Nausea, Pain in extremity, Pyrexia
SMQs:, Acute pancreatitis (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Guillain-Barre syndrome (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Vestibular disorders (broad), Tendinopathies and ligament disorders (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? Yes
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No concurrent medication
Current Illness: Unknown
Preexisting Conditions: The subject has no relevant medical history and no history of adverse events following previous vaccinations.
Allergies:
Diagnostic Lab Data: UNK
CDC Split Type: A0924841A

Write-up: This case was reported by a healthcare professional and described the occurrence of headache in a 13-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Concurrent vaccination included HAVRIX (GlaxoSmithKline), MENACTRA (Sanofi), MMR II (Merck), ADACEL (Sanofi) and VARIVAX (Merck) all given on 12 April 2011. There were no concurrent medications. On 12 April 2011 the subject received 1st dose of CERVARIX at 0.5 ml in the left arm. On the night of 12 April 2011, less than one day after vaccination with CERVARIX, the subject experienced headache, dizziness, nausea, arm pain, tactile fever and body weakness. At the time of reporting the events were improved. Follow-up information received on 13 May 2011 indicated that the events resolved.


VAERS ID: 431144 (history)  
Form: Version 1.0  
Age: 17.0  
Sex: Female  
Location: California  
Vaccinated:2011-08-06
Onset:2011-08-15
   Days after vaccination:9
Submitted: 2011-08-15
   Days after onset:0
Entered: 2011-08-25
   Days after submission:10
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (VAQTA) / MERCK & CO. INC. AHAVB384AA / 1 RA / UN
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS 0476AA / 1 RA / UN
TDAP: TDAP (BOOSTRIX) / GLAXOSMITHKLINE BIOLOGICALS AVP03958BA / 6 LA / UN
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. 0167AA / 1 LA / UN

Administered by: Public       Purchased by: Public
Symptoms: Injection site erythema, Injection site oedema, Injection site warmth, Local reaction
SMQs:, Extravasation events (injections, infusions and implants) (broad), Haemodynamic oedema, effusions and fluid overload (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: None
Preexisting Conditions: None
Allergies:
Diagnostic Lab Data:
CDC Split Type:

Write-up: Local reaction on right deltoid area, edema & erythema measuring 30 mm x 30 mm. Increased temperature on same area. Pt c/o no other symptoms.


VAERS ID: 432426 (history)  
Form: Version 1.0  
Age: 36.0  
Sex: Unknown  
Location: Texas  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2011-08-31
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA088BC / UNK RA / IM
YF: YELLOW FEVER (YF-VAX) / SANOFI PASTEUR UH101AA / UNK LA / SC

Administered by: Other       Purchased by: Private
Symptoms: Injection site erythema
SMQs:, Extravasation events (injections, infusions and implants) (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type:

Write-up: Localized redness at injection site of yellow fever.


VAERS ID: 434220 (history)  
Form: Version 1.0  
Age: 18.0  
Sex: Female  
Location: Puerto Rico  
Vaccinated:2011-06-22
Onset:2011-06-22
   Days after vaccination:0
Submitted: 2011-09-13
   Days after onset:83
Entered: 2011-09-13
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEPA: HEP A (VAQTA) / MERCK & CO. INC. 0368AA / 1 LA / IM
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPV096AC / 1 UN / IM
MNQ: MENINGOCOCCAL CONJUGATE (MENVEO) / NOVARTIS VACCINES AND DIAGNOSTICS M10047 / UNK LA / IM
TDAP: TDAP (ADACEL) / SANOFI PASTEUR M3491CA / UNK RA / IM
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. 0044AA / 2 UN / IM

Administered by: Public       Purchased by: Other
Symptoms: Asthenia, Headache, Hypersensitivity, Nausea, Rash generalised, Swelling
SMQs:, Anaphylactic reaction (broad), Acute pancreatitis (broad), Angioedema (broad), Guillain-Barre syndrome (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Haemodynamic oedema, effusions and fluid overload (narrow), Hypersensitivity (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: PATIENT HAD VARICELLA
Current Illness:
Preexisting Conditions: PATIENT ALLERGIC TO ACETAMINOPHEN, ASA AND PENICILLIN
Allergies:
Diagnostic Lab Data:
CDC Split Type: PR1111

Write-up: ALLERGIC REACTION IN BOTH EYES, ALLOVER RASH, WEAKNESS, NAUSEA, HEADACHE AND SWELLING.


VAERS ID: 435065 (history)  
Form: Version 1.0  
Age: 16.0  
Sex: Female  
Location: Ohio  
Vaccinated:2011-09-13
Onset:0000-00-00
Submitted: 2011-09-19
Entered: 2011-09-21
   Days after submission:2
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA113AA / 2 LA / IM
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. 0602AA / 2 LA / SC

Administered by: Private       Purchased by: Public
Symptoms: Erythema, Injection site induration, Injection site pruritus
SMQs:, Anaphylactic reaction (broad), Extravasation events (injections, infusions and implants) (broad), Hypersensitivity (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: PCN allergy; Paroxysmal tachycardia
Allergies:
Diagnostic Lab Data: None
CDC Split Type:

Write-up: Local erythema & induration, intense pruritus (L) upper arm. Rx antihistamines.


Result pages: prev   1 2 3 4 5 6 7 8 9 10 11 12 13 14   next

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=5&VAX=HPV2


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166